FASLG and autoimmune polyendocrinopathy: Some case reports showed the efficacy of rituximab combined with plasmapheresis on APS cutaneous involvement [85,86] with the aim to remove aPL by plasma exchange and block the production of new antibodies by depleting B cells [86].